1. Clinical & Scientific Overview
Valsartan (ARNI Co-Crystal FDC) (TIP-MED-000273, Reference Code [3.36]-C3) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Angiotensin Receptor–Neprilysin Inhibitor (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [3.36] (Sacubitril + Valsartan (ARNI)). Representative Indian Market Examples (Edition 2.7 Ch 03 [3.36], p. 38): Vymada (Novartis), Cidmus (Lupin), Azmarda (Cipla), Arnipin (Torrent) — Strengths & Dosage Forms: Film-Coated Tablets: 50 mg (24 mg Sacubitril + 26 mg Valsartan), 100 mg (49/51 mg), 200 mg (97/103 mg)
Film-Coated Tablets: 50 mg (24 mg Sacubitril + 26 mg Valsartan), 100 mg (49/51 mg), 200 mg (97/103 mg)
3. Mechanism of Action & Pharmacodynamics
Angiotensin Receptor–Neprilysin Inhibitor (Schedule H) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Angiotensin Receptor–Neprilysin Inhibitor (Schedule H) for Chronic Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF <=40%, NYHA Class II–IV) to reduce cardiovascular death and HF hospitalisation.
4. Therapeutic Indications & Evidence-Supported Uses
- Chronic Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF <=40%, NYHA Class II–IV) to reduce cardiovascular death and HF hospitalisation
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Start 50 mg (24/26 mg) or 100 mg (49/51 mg) PO BD; double dose every 2–4 weeks as tolerated to target maintenance dose of 200 mg (97/103 mg) BD
Administration & Meal Timing: May be taken with or without food; swallow whole | Morning & Evening (12-hourly BD)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [3.36].
Renal: If eGFR <30 mL/min, initiate at 50 mg (24/26 mg) BD and titrate cautiously. Hepatic: Start 50 mg BD in Child–Pugh B; contraindicated in Child–Pugh C
Renal: If eGFR <30 mL/min, initiate at 50 mg (24/26 mg) BD and titrate cautiously. Hepatic: Start 50 mg BD in Child–Pugh B; contraindicated in Child–Pugh C
Renal: If eGFR <30 mL/min, initiate at 50 mg (24/26 mg) BD and titrate cautiously. Hepatic: Start 50 mg BD in Child–Pugh B; contraindicated in Child–Pugh C
7. Contraindications, Precautions & High-Risk Warnings
- MANDATORY 36-HOUR WASHOUT FROM ANY ACE INHIBITOR: Strictly contraindicated within 36 hours of taking Ramipril, Enalapril, Perindopril, or Lisinopril (life-threatening angioedema!). Contraindicated in pregnancy (teratogenic), history of angioedema, and concomitant ARB use (already contains Valsartan!)
Key Clinical Precautions: Renal: If eGFR <30 mL/min, initiate at 50 mg (24/26 mg) BD and titrate cautiously. Hepatic: Start 50 mg BD in Child–Pugh B; contraindicated in Child–Pugh C
8. Adverse Effects Profile
- Symptomatic hypotension (15–18%), hyperkalaemia, cough, dizziness, mild eGFR dip
- Life-threatening laryngeal/airway angioedema, acute kidney injury, severe hyperkalaemia (K+ >5.5 mEq/L), foetal toxicity
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- NEVER combine with an ACE inhibitor (<36h washout) or another ARB (Telmisartan/Losartan — duplicate!)
- Potassium-sparing diuretics (Spironolactone/Eplerenone) and K+ supplements increase hyperkalaemia risk; NSAIDs cause Triple Whammy AKI; increases Atorvastatin Cmax
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [3.36].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: COUNTER RED-FLAG CHECK: Confirm patient has STOPPED any ACE inhibitor (Ramipril/Enalapril) for at least 36 hours before taking first Vymada/Cidmus tablet, and is NOT taking Telmisartan/Losartan concurrently! Seek emergency care if lip/tongue swelling occurs
- Meal & Clock Timing Instruction: May be taken with or without food; swallow whole (Morning & Evening (12-hourly BD))
- Missed Dose Protocol: Take within 6 hours if remembered; otherwise skip and take next scheduled BD dose
- Geriatric Dispensing Pearl: Initiate at 50 mg BD in elderly patients >=75 years or with SBP 100–110 mmHg; monitor orthostatic BP
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Film-Coated Tablets: 50 mg (24 mg Sacubitril + 26 mg Valsartan), 100 mg (49/51 mg), 200 mg (97/103 mg)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.5] Ramipril — Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted
- [3.6] Enalapril Maleate — Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted
- [3.7] Metoprolol (Metoprolol Succinate ER & Metoprolol Tartrate IR) — Cardioselective Beta-1 Adrenergic Blocker
